Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.
dc.contributor.author | Zhu, Mei-Ling | |
dc.contributor.author | Wang, Mengyun | |
dc.contributor.author | Cao, Zhi-Gang | |
dc.contributor.author | He, Jing | |
dc.contributor.author | Shi, Ting-Yan | |
dc.contributor.author | Xia, Kai-Qin | |
dc.contributor.author | Qiu, Li-Xin | |
dc.contributor.author | Wei, Qing-Yi | |
dc.date.accessioned | 2019-02-01T15:11:18Z | |
dc.date.available | 2019-02-01T15:11:18Z | |
dc.date.issued | 2012-01 | |
dc.date.updated | 2019-02-01T15:11:17Z | |
dc.description.abstract | BACKGROUND: Excision repair cross complementing group 5 (ERCC5 or XPG) plays an important role in regulating DNA excision repair, removal of bulky lesions caused by environmental chemicals or UV light. Mutations in this gene cause a rare autosomal recessive syndrome, and its functional single nucleotide polymorphisms (SNPs) may alter DNA repair capacity phenotype and cancer risk. However, a series of epidemiological studies on the association between the ERCC5 Asp1104His polymorphism (rs17655, G>C) and cancer susceptibility generated conflicting results. METHODOLOGY/PRINCIPAL FINDINGS: To derive a more precise estimation of the association between the ERCC5 Asp1104His polymorphism and overall cancer risk, we performed a meta-analysis of 44 published case-control studies, in which a total of 23,490 cases and 27,168 controls were included. To provide additional biological plausibility, we also assessed the genotype-gene expression correlation from the HapMap phase II release 23 data with 270 individuals from 4 ethnic populations. When all studies were pooled, we found no statistical evidence for a significantly increased cancer risk in the recessive genetic models (His/His vs. Asp/Asp: OR = 0.99, 95% CI: 0.92-1.06, P = 0.242 for heterogeneity or His/His vs. Asp/His + Asp/Asp: OR = 0.98, 95% CI: 0.93-1.03, P = 0.260 for heterogeneity), nor in further stratified analyses by cancer type, ethnicity, source of controls and sample size. In the genotype-phenotype correlation analysis from 270 individuals, we consistently found no significant correlation of the Asp1104His polymorphism with ERCC5 mRNA expression. CONCLUSIONS/SIGNIFICANCE: This meta-analysis suggests that it is unlikely that the ERCC5 Asp1104His polymorphism may contribute to individual susceptibility to cancer risk. | |
dc.identifier | PONE-D-12-03281 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Public Library of Science (PLoS) | |
dc.relation.ispartof | PloS one | |
dc.relation.isversionof | 10.1371/journal.pone.0036293 | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Genetic Predisposition to Disease | |
dc.subject | Endonucleases | |
dc.subject | DNA-Binding Proteins | |
dc.subject | Nuclear Proteins | |
dc.subject | Transcription Factors | |
dc.subject | RNA, Messenger | |
dc.subject | Gene Expression Regulation, Neoplastic | |
dc.subject | Polymorphism, Single Nucleotide | |
dc.title | Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis. | |
dc.type | Journal article | |
duke.contributor.orcid | Wei, Qing-Yi|0000-0002-3845-9445|0000-0003-4115-4439 | |
pubs.begin-page | e36293 | |
pubs.issue | 7 | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Population Health Sciences | |
pubs.organisational-group | Basic Science Departments | |
pubs.organisational-group | Medicine, Medical Oncology | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Clinical Science Departments | |
pubs.publication-status | Published | |
pubs.volume | 7 |
Files
Original bundle
- Name:
- Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.pdf
- Size:
- 567.89 KB
- Format:
- Adobe Portable Document Format